Rifai N - Search Results

1

Blood pressure, C-reactive protein, and risk of future cardiovascular events.

Blake GJ, Rifai N, Buring JE, Ridker PM. Blake GJ, et al. Among authors: rifai n. Circulation. 2003 Dec 16;108(24):2993-9. doi: 10.1161/01.CIR.0000104566.10178.AF. Epub 2003 Nov 24. Circulation. 2003. PMID: 14638538

2

C-reactive protein and the risk of developing hypertension.

Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. Sesso HD, et al. Among authors: rifai n. JAMA. 2003 Dec 10;290(22):2945-51. doi: 10.1001/jama.290.22.2945. JAMA. 2003. PMID: 14665655

3

Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk.

Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, Mullington JM. Meier-Ewert HK, et al. Among authors: rifai n. J Am Coll Cardiol. 2004 Feb 18;43(4):678-83. doi: 10.1016/j.jacc.2003.07.050. J Am Coll Cardiol. 2004. PMID: 14975482 Free article. Clinical Trial.

4

High-sensitivity C-reactive protein: clinical importance.

Bassuk SS, Rifai N, Ridker PM. Bassuk SS, et al. Among authors: rifai n. Curr Probl Cardiol. 2004 Aug;29(8):439-93. Curr Probl Cardiol. 2004. PMID: 15258556 Review.

5

Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.

Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM. Schaumberg DA, et al. Among authors: rifai n. Circulation. 2005 May 17;111(19):2446-53. doi: 10.1161/01.CIR.0000165064.31505.3B. Epub 2005 May 2. Circulation. 2005. PMID: 15867184 Clinical Trial.

6

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.

Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Ridker PM, et al. Among authors: rifai n. JAMA. 2005 Jul 20;294(3):326-33. doi: 10.1001/jama.294.3.326. JAMA. 2005. PMID: 16030277

7

Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.

Ridker PM, Danielson E, Rifai N, Glynn RJ; Val-MARC Investigators. Ridker PM, et al. Among authors: rifai n. Hypertension. 2006 Jul;48(1):73-9. doi: 10.1161/01.HYP.0000226046.58883.32. Epub 2006 May 19. Hypertension. 2006. PMID: 16714425 Clinical Trial.

8

Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.

Mora S, Rifai N, Buring JE, Ridker PM. Mora S, et al. Among authors: rifai n. Circulation. 2006 Aug 1;114(5):381-7. doi: 10.1161/CIRCULATIONAHA.106.634089. Epub 2006 Jul 24. Circulation. 2006. PMID: 16864722

9

Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.

Suk Danik J, Rifai N, Buring JE, Ridker PM. Suk Danik J, et al. Among authors: rifai n. JAMA. 2006 Sep 20;296(11):1363-70. doi: 10.1001/jama.296.11.1363. JAMA. 2006. PMID: 16985228

10

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

Ridker PM, Buring JE, Rifai N, Cook NR. Ridker PM, et al. Among authors: rifai n. JAMA. 2007 Feb 14;297(6):611-9. doi: 10.1001/jama.297.6.611. JAMA. 2007. PMID: 17299196

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

546 results

Search Page

Filters